CytomX Operating Income from 2010 to 2024

CTMX Stock

USD 1.06 0.04 3.92%

CytomX Therapeutics Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income will likely drop to about -6.8 M in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit CytomX Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

2013-12-31

Previous Quarter

-8.5 M

Current Value

4.1 M

Quarterly Volatility

10.5 M

Yuan Drop

Covid

Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.1 M or Selling General Administrative of 28.8 M, as well as many indicators such as Price To Sales Ratio of 1.07, Dividend Yield of 0.0299 or Days Sales Outstanding of 11.76. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.

Check out the analysis of CytomX Therapeutics Correlation against competitors.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

Latest CytomX Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of CytomX Therapeutics over the last few years. Operating Income is the amount of profit realized from CytomX Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of CytomX Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. CytomX Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

CytomX Operating Income Regression Statistics

	Arithmetic Mean	(44,294,613)
	Coefficient Of Variation	(79.23)
	Mean Deviation	29,103,028
	Median	(33,203,000)
	Standard Deviation	35,096,048
	Sample Variance	1231.7T
	Range	104.4M
	R-Value	(0.38)
	Mean Square Error	1137.4T
	R-Squared	0.14
	Significance	0.17
	Slope	(2,962,573)
	Total Sum of Squares	17244.3T

CytomX Operating Income History

	2024	-6.8 M
	2023	-6.5 M
	2022	-101.3 M
	2021	-83.8 M
	2020	-48.6 M
	2019	-110.9 M
	2018	-77.9 M

Other Fundumenentals of CytomX Therapeutics

Non Operating Income Net Other

CytomX Therapeutics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Deferred Long Term Liab	Short Long Term Debt	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.65	0.56	-0.84	-0.6	0.67	0.19	-0.11	0.9	0.89	1.0	0.55	-0.52	-0.11	0.44	0.84	0.82	-0.11	0.56	-0.02	-0.29	-0.11
Total Stockholder Equity	0.65		-0.12	-0.63	0.05	0.78	-0.33	0.28	0.61	0.24	0.66	0.69	0.1	0.28	0.21	0.9	0.18	0.28	0.0	0.57	0.34	0.28
Current Deferred Revenue	0.56	-0.12		-0.22	-0.98	0.08	0.49	-0.68	0.59	0.74	0.53	0.14	-0.94	-0.68	0.27	0.26	0.88	-0.68	0.88	-0.77	-0.94	-0.68
Net Debt	-0.84	-0.63	-0.22		0.32	-0.64	-0.28	-0.38	-0.63	-0.76	-0.84	-0.38	0.29	-0.38	-0.35	-0.73	-0.53	-0.38	-0.38	-0.22	-0.06	-0.38
Retained Earnings	-0.6	0.05	-0.98	0.32		-0.13	-0.5	0.57	-0.59	-0.76	-0.57	-0.11	0.97	0.57	-0.36	-0.33	-0.89	0.57	-0.94	0.73	0.93	0.57
Accounts Payable	0.67	0.78	0.08	-0.64	-0.13		0.05	0.12	0.63	0.39	0.69	0.79	0.02	0.12	0.3	0.86	0.24	0.12	0.03	0.21	0.14	0.12
Net Receivables	0.19	-0.33	0.49	-0.28	-0.5	0.05		-0.03	0.2	0.47	0.19	0.04	-0.45	-0.03	-0.05	0.0	0.33	-0.03	0.38	-0.69	-0.45	-0.03
Good Will	-0.11	0.28	-0.68	-0.38	0.57	0.12	-0.03		-0.24	-0.18	-0.11	-0.06	0.47	1.0	-0.07	0.07	-0.47	1.0	-0.37	0.6	0.74	1.0
Short Term Investments	0.9	0.61	0.59	-0.63	-0.59	0.63	0.2	-0.24		0.78	0.91	0.75	-0.52	-0.24	0.29	0.82	0.78	-0.24	0.54	-0.15	-0.35	-0.24
Total Liab	0.89	0.24	0.74	-0.76	-0.76	0.39	0.47	-0.18	0.78		0.87	0.29	-0.72	-0.18	0.44	0.53	0.92	-0.18	0.73	-0.33	-0.51	-0.18
Total Current Assets	1.0	0.66	0.53	-0.84	-0.57	0.69	0.19	-0.11	0.91	0.87		0.58	-0.49	-0.11	0.41	0.84	0.8	-0.11	0.53	0.0	-0.26	-0.11
Short Term Debt	0.55	0.69	0.14	-0.38	-0.11	0.79	0.04	-0.06	0.75	0.29	0.58		-0.01	-0.06	-0.06	0.78	0.23	-0.06	0.04	0.11	0.08	-0.06
Intangible Assets	-0.52	0.1	-0.94	0.29	0.97	0.02	-0.45	0.47	-0.52	-0.72	-0.49	-0.01		0.47	-0.32	-0.25	-0.85	0.47	-0.98	0.69	0.9	0.47
Common Stock	-0.11	0.28	-0.68	-0.38	0.57	0.12	-0.03	1.0	-0.24	-0.18	-0.11	-0.06	0.47		-0.07	0.07	-0.47	1.0	-0.37	0.6	0.74	1.0
Property Plant Equipment	0.44	0.21	0.27	-0.35	-0.36	0.3	-0.05	-0.07	0.29	0.44	0.41	-0.06	-0.32	-0.07		0.28	0.46	-0.07	0.35	-0.11	-0.28	-0.07
Net Tangible Assets	0.84	0.9	0.26	-0.73	-0.33	0.86	0.0	0.07	0.82	0.53	0.84	0.78	-0.25	0.07	0.28		0.47	0.07	0.32	0.19	-0.03	0.07
Deferred Long Term Liab	0.82	0.18	0.88	-0.53	-0.89	0.24	0.33	-0.47	0.78	0.92	0.8	0.23	-0.85	-0.47	0.46	0.47		-0.47	0.84	-0.45	-0.72	-0.47
Short Long Term Debt	-0.11	0.28	-0.68	-0.38	0.57	0.12	-0.03	1.0	-0.24	-0.18	-0.11	-0.06	0.47	1.0	-0.07	0.07	-0.47		-0.37	0.6	0.74	1.0
Capital Surpluse	0.56	0.0	0.88	-0.38	-0.94	0.03	0.38	-0.37	0.54	0.73	0.53	0.04	-0.98	-0.37	0.35	0.32	0.84	-0.37		-0.58	-0.83	-0.37
Net Invested Capital	-0.02	0.57	-0.77	-0.22	0.73	0.21	-0.69	0.6	-0.15	-0.33	0.0	0.11	0.69	0.6	-0.11	0.19	-0.45	0.6	-0.58		0.88	0.6
Net Working Capital	-0.29	0.34	-0.94	-0.06	0.93	0.14	-0.45	0.74	-0.35	-0.51	-0.26	0.08	0.9	0.74	-0.28	-0.03	-0.72	0.74	-0.83	0.88		0.74
Capital Stock	-0.11	0.28	-0.68	-0.38	0.57	0.12	-0.03	1.0	-0.24	-0.18	-0.11	-0.06	0.47	1.0	-0.07	0.07	-0.47	1.0	-0.37	0.6	0.74

Click cells to compare fundamentals

About CytomX Therapeutics Financial Statements

CytomX Therapeutics investors use historical fundamental indicators, such as CytomX Therapeutics' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-6.5 M	-6.8 M
Non Operating Income Net Other	154.8 K	147.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CytomX Operating Income from 2010 to 2024

Latest CytomX Therapeutics' Operating Income Growth Pattern

CytomX Operating Income Regression Statistics

CytomX Operating Income History

Other Fundumenentals of CytomX Therapeutics

CytomX Therapeutics Operating Income component correlations

About CytomX Therapeutics Financial Statements

Also Currently Popular

Additional Tools for CytomX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY